Overview
- The Georgetown-led simulation published in JAMA Network Open on Nov. 10, 2026 estimated that anthracycline-based chemotherapy could cut a survivor’s median remaining life expectancy by about 9.4 years because of earlier onset of aging-related diseases.
- Researchers modeled 400 million U.S. women aged 30 to 79 using an established CISNET breast cancer simulation combined with published data on the p16 biomarker to translate chemotherapy-driven increases in cellular senescence into lifetime health outcomes.
- The team links chemotherapy to accumulation of p16-positive senescent cells that promote inflammation and tissue damage, which the model projects will raise non–breast-cancer morbidity and mortality at younger ages.
- Study authors emphasize that chemotherapy improves cancer survival and that these results are simulation-based estimates, not longitudinal patient follow-up, so clinicians should not change treatment decisions on this evidence alone.
- The paper calls for adding biological-age assessment to survivorship care, testing behavioral and drug interventions such as exercise programs and senolytics to mitigate age acceleration, and expanding empirical and modeling work to other treatments and patient groups.